dermatomyositis Archives - Page 23 of 28

Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Timothy B. Niewold¹, Alexander Meves², Julia S. Lehman³, Karin Popovic-Silwerfeldt⁴, Cristine Charlesworth⁵, Marie Wahren-Herlenius⁶, Elisabet Svenungsson⁷ and Vilija Oke⁸, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Cancer Cenetr, Dermatology, Mayo Clinic, Rochester, MN, ³Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ⁴Department of Clinical Sciences, Dermatology Clinic, Danderyds Hospital,, Stockholm, Sweden, ⁵Mayo Clinic, Rochester, MN, ⁶Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…
Abstract Number: 1331 • 2018 ACR/ARHP Annual Meeting
Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome
Yves Allenbach¹, Yurdagul Uzunhan², Ségolène Toquet³, Gaëlle Leroux⁴, Laure Gallay⁵, Aude Rigolet⁶, Baptiste Hervier⁶, Nicolas Champtiaux⁶, Mathieu Vautier⁶, Perrine Guillaume⁶, Nicolas Limal⁷, Alain Meyer⁸, Christophe Deligny⁹, Bernard Bonnotte¹⁰, Hervé Devilliers¹¹, Sylvain Audia¹², Maxime Samson¹³, Amélie Servettaz¹⁴, Nathalie Costedoat¹⁵, David Saadoun¹⁶, elisabeth diot¹⁷, Alice Berezne¹⁸, Arsène Mékinian¹⁹, Kuberaka Mariampillai²⁰, Hilario Nunes² and Olivier Benveniste⁶, ¹Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, ²Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ³Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology., Paris, France, ⁴Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁵Internal Medicine, Université de Lyon - CHU Lyon, Lyon, France, ⁶Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ⁷Internal Medicine, APHP - Henri Mondor Hospital, Paris, France, ⁸15Département de Rhumatologie, Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁰Dijon, Dijon, France, ¹¹Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, ¹²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Internal Medicine, CHU - Reims University, Reims, France, ¹⁵Internal Medicine, Paris Descartes Université - APHP, paris, France, ¹⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ¹⁷Internal Medicine, Université Tours - CHU, Tours, France, ¹⁸Internal Medicine, CH Annecy, Annecy, France, ¹⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁰Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France
Background/Purpose: Dermatomyositis (DM) is a heterogenous group of diseases ranging from skin limited disorders to non-specific auto-immune diseases with patients suffering from additional extra-cutaneous manifestations.…
Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Yuji Hosono¹, Iago Pinal-Fernandez¹, Katherine Pak¹, Jemima Albayda², Eleni Tiniakou³, Julie J. Paik⁴, Christopher A. Mecoli⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶ and Andrew Mammen^1,7, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
Abstract Number: 2158 • 2017 ACR/ARHP Annual Meeting
HLA-DRB1*04:03/*04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population
Yukie Yamaguchi¹, Masataka Kuwana², Miwa Kanaoka¹, Tomoya Watanabe¹, Naoko Okiyama³, Takahisa Gono², Masanari Kodera⁴, Takeshi Kambara⁵, Yasuhito Hamaguchi⁶, Mariko Seishima⁷, Kazuhiko Takehara⁶, Manabu Fujimoto³ and Michiko Aihara¹, ¹Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Dermatology, University of Tsukuba, Tsukuba, Japan, ⁴Department of Dermatology, Japan Community Health care Organization Chukyo Hospital, Nagoya, Japan, ⁵Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan, ⁶Department of Dermatology, Kanazawa University, Kanazawa, Japan, ⁷Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan
Background/Purpose: Dermatomyositis (DM) is characterized by inflammation of the skin and skeletal muscle, and is occasionally complicated by interstitial lung disease or concomitant malignancy. It…
Abstract Number: 2159 • 2017 ACR/ARHP Annual Meeting
Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings
Majid Zeidi^1,2, Peter B Chansky^1,2 and Victoria P Werth^3,4, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, PHILADELPHIA, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and the VA Medical Center, Philadelphia, PA, ⁴Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose : The use of complementary and alternative medicine (CAM) has gained popularity in the United States over the last few decades. Herbal supplements have…
Abstract Number: 2164 • 2017 ACR/ARHP Annual Meeting
Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies
Masashi Taniguchi¹, Ran Nakashima¹, Nobuo Kuramoto¹, Kosaku Murakami¹, Motomu Hashimoto², Hajime Yoshifuji¹, Masao Tanaka², Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (Abs), which mainly consists of anti-Jo1, PL-7, PL-12, EJ, OJ and KS, are the most common myositis-specific autoantibodies (MSAs). It has…
Abstract Number: 2165 • 2017 ACR/ARHP Annual Meeting
Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Jason Weiner¹, Ryan Jessee², Amanda M. Eudy³, Robert T. Keenan⁴, Michael Datto⁵ and Lisa Criscione-Schreiber⁶, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Rheumatology, NYU-HJD, New York, NY, ⁵Department of Pathology, Duke University, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Myositis autoantibodies have diagnostic, therapeutic and prognostic implications, but their utility in clinical practice is unclear. We aimed to describe our institutionÕs ordering practices…
Abstract Number: 2169 • 2017 ACR/ARHP Annual Meeting
A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study
Kimberly A. Rehberg¹, Morgan M. Brown², Anna K. Shmagel¹, Elie Gertner³ and Jerry A. Molitor¹, ¹Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²HealthPartners Institute, St. Paul, MN, ³Section of Rheumatology, Regions Hospital, St. Paul, MN
Background/Purpose: Recent studies have suggested the possible benefit of the anti-CD20 agent Rituximab (RTX) in autoimmune myositis (AIM). As AIM is a rare and heterogeneous…
Abstract Number: 2170 • 2017 ACR/ARHP Annual Meeting
Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays
Makoto Miyara¹, Rémi Chieze², Yurdagul Uzunhan³, Jean- Luc Charuel⁴, Pascale Ghillani-Dalbin⁴, Sasi Mudumba⁵, Alice Wu⁵, Hilario Nunes³, Zahir Amoura⁶, Rufus Burlingame⁵ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁴Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Genalyte Inc., San Diego, CA, ⁶Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: The presence of anti-MDA5 antibody is associated with amyopathic dermatomyositis and/or rapidly progressive interstitial lung disease that can be fatal.In the latter case, it…
Abstract Number: 851 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease
Silvia Martinez¹, Rohit Aggarwal^2,3 and Chester V. Oddis⁴, ¹Internal Medicine, UPMC, pittsburgh, PA, ²Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Interstitial lung disease (ILD) significantly contributes to morbidity and mortality in adult polymyositis (PM) and dermatomyositis (DM). Myositis associated autoantibodies (MAA) are associated with…
Abstract Number: 2172 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis
Nobuaki Ikeda, Yukie Yamaguchi, Miwa Kanaoka, Yasushi Ototake, Eriko Takebayashi and Michiko Aihara, Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Dermatomyositis (DM) is an autoimmune inflammatory disease characterized by skin eruptions and myositis, which is occasionally complicated by interstitial lung disease (ILD) or concomitant…
Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Juan J Maya, Olga Pinkston, Florentina Berianu, Benjamin Wang and Andy Abril, Rheumatology, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…
Abstract Number: 1732 • 2017 ACR/ARHP Annual Meeting
The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: In dermatomyositis (DM) and polymyositis (PM), the characteristics of T cell expression in peripheral blood have been previously described; especially, decreased expression of interferon-γ…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…

Abstracts tagged "dermatomyositis"

Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)

Moving from Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibody to Anti-Melanoma Differentiation-Associated Gene 5 Syndrome

Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States

HLA-DRB104:03/04:06 As the Genetic Susceptibility to Dermatomyositis Positive for Anti-Transcriptional Intermediary Factor 1-γ Antibody in Japanese Population

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

Prognostic Factors in Polymyositis/ Dermatomyositis Patients with Anti-Synthetase Antibodies

Easily Obtainable Myositis Autoantibody Panel Predictive Factors

A Two-Center Experience with Rituximab in Patients with Primary Idiopathic Myositis and Overlap Myositis: A Retrospective Observational Study

Near Patient Detection of Anti-MDA5 Antibodies Using Photonic Ring Immunoassays

Autoantibodies Predict Long Term Survival in Myositis Associated Interstitial Lung Disease

Clinical Significance of Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Antibody in Patients with Dermatomyositis

Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers

Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies

The Characteristic T-Cell Receptor-Mediated Signaling of Peripheral Blood T Cells in Dermatomyositis and Polymyositis

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients